 President, several years ago I started looking at the financial relationships between physicians and drug companies. I first began these inquiries by examining payments from pharmaceutical companies to physicians serving on Food and Drug Administration advisory boards. More recently, I began looking at professors at medical schools and their financial relationships with pharmaceutical companies. In turn, I scrutinized the grants that these physicians may have received from the National Institutes of Health.  I first examined a psychiatrist at the University of Cincinnati. Then I looked at three research psychiatrists who took millions of dollars from the drug companies and failed to fully report their financial relationships to Harvard and Mass General Hospital.  I then discovered a doctor at Stanford who founded a company that is seeking the Food and Drug Administration's approval to market a drug for psychotic depression. The National Institutes of Health is funding some of the research on this drug, which is being led by this same Stanford scientist. If his own research finds that the drug is successful, this researcher stands to gain millions. The NIH later removed this researcher from the grant.  I would now like to address two doctors with the University of Texas System.  Dr. Augustus John Rush is a psychiatrist at the University of Texas Southwestern Medical Center. During 2003-2005, Dr. Rush received an NIH grant to conduct a clinical training program. This program helped trainees understand how to conduct proper clinical trials and also dealt with medical ethics.  However, just 2 years before getting this Federal grant, Dr. Rush failed to report all of the money that Eli Lilly paid him. Dr. Rush disclosed $3,000 in payments from the company, but Eli Lilly tells me that they paid Dr. Rush $17,802 in 2001.  I would also like to discuss Dr. Karen Wagner, a professor at the University of Texas Medical Branch at Galveston.  Dr. Wagner was one of the authors on a Paxil study known as Study 329. This study was published in 2001.  Study 329 was cited in a New York case where GlaxoSmithKline was charged with ``repeated and persistent fraud.'' Part of the case against Glaxo was that the drug company promoted positive findings but didn't publicize unfavorable data.  In March 2006, Dr. Wagner was being deposed in a case on Paxil. During that deposition, Dr. Wagner was asked how much money she had taken from drug companies over the previous 5 years.  Her response? She said: ``I don't know.'' In fact, she testified that she couldn't even estimate how much money she received from the drug companies.  According to Glaxo, they paid Dr. Wagner over $53,220 in 2000. In 2001, when study 329 was published the company reported paying her $18,255.  During many of these years, Dr. Wagner has led NIH-funded studies on depression. These studies involved Paxil and Prozac; an antidepressant made by Eli Lilly. Eli Lilly reported to me that they paid Dr. Wagner over $11,000 in 2002. However, Dr. Wagner did not disclose this payment to the University of Texas.  Apparently, the University of Texas Medical Branch didn't require their physicians to disclose their financial relationships with the drug industry, until around 2002. But federal guidelines from 1995 are clear that researchers need to disclose this money when they take a grant from the NIH.  What makes this even more interesting is that from September 2003 through August 2004, Dr. Wagner was a voting member of the Conflict of Interest Committee at her university. That is right, she was one of the university's experts on conflicts of interest during the same time that she was not reporting her outside income.  Before closing, I would like to say that the University of Texas System has been very cooperative in this investigation. And I appreciate the continued cooperation of companies like GlaxoSmithKline and Eli Lilly.  I ask unanimous consent to have my letter to the University of Texas printed in the Record.  There being no objection, the material was ordered to be printed in the Record, as follows:                                                      U.S. Senate,                                         Committee on Finance,                                Washington, DC, September 9, 2008.     Mark G. Yudof,     Chancellor, The University of Texas System, Austin, TX.          78701.       Dear Mr. Yudof: The United States Senate Committee on      Finance (Committee) has jurisdiction over the Medicare and      Medicaid programs and, accordingly, a responsibility to the      more than 80 million Americans who receive health care      coverage under these programs. As Ranking Member of the      Committee, I have a duty to protect the health of Medicare      and Medicaid beneficiaries and safeguard taxpayer dollars      appropriated for these programs. The actions taken by      recognized experts, like those at the University of Texas      (University/Texas System) system's medical schools who are      discussed throughout this letter, often have a profound      impact upon the decisions made by taxpayer funded programs      like Medicare and Medicaid and the way that patients are      treated and funds expended.       Moreover, and as has been detailed in several studies and      news reports, funding by pharmaceutical companies can      influence scientific studies, continuing medical education,      and the prescribing patterns of doctors. Because I am      concerned that there has been little transparency on this      matter, I have sent letters to almost two dozen research      universities across the United States. In these letters, I      asked questions about the conflict of interest disclosure      forms signed by some of their faculty. Universities require      doctors to report their related outside income, but I am      concerned that these requirements are sometimes disregarded.       I have also been taking a keen interest in the almost $24      billion annually appropriated to the National Institutes of      Health (NIH) to fund grants at various institutions such as      yours. As you know, institutions are required to manage a      grantee's conflicts of interest. But I am learning that this      task is made difficult because physicians do not consistently      report all the payments received from drug and device      companies.       To bring some greater transparency to this issue, Senator      Kohl and I introduced the Physician Payments Sunshine Act      (Act). This Act will require drug and device companies to      report publicly any payments that they make to doctors,      within certain parameters.       I am writing to assess the implementation of financial      disclosure policies of the University of Texas system. In      response to my letters of October 26, 2007, your University      provided me with the financial disclosure reports that Dr.      Augustus John Rush, Jr., at the University of Texas      Southwestern Medical Center at Dallas (UTSW) and Dr. Karen      Wagner at the University of Texas Medical Branch at Galveston      (UTMB) filed during the period of January 2000 through June      2007. (the Physicians)       My staff investigators carefully reviewed each of the      Physicians' disclosure forms and detailed the payments      disclosed. I then asked that the University confirm the      accuracy of the information. In February 2008 your counsel      provided clarification and additional information from the      Physicians pursuant to my inquiry.       In addition, I contacted executives at several major      pharmaceutical companies and device manufacturers (the      Companies) and asked them to list the payments that they made      to Drs. Wagner and Rush during the years 2000 through 2007.      These Companies voluntarily and cooperatively reported      additional payments that the Physicians do not appear to have      disclosed to the University.       Because these disclosures do not match, I am attaching a      chart intended to provide a few examples of the data reported      to me. This chart contains columns showing the payments      disclosed in the forms the Physicians filed with the      University and amounts reported by some of the Companies.       I understand that UTMB did not require that dollar amounts      be reported in financial disclosures until 2002, despite      federal requirements which required such reporting for NIH      grantees in 1995. I also understand that UTSW's disclosures      do not disclose if payments were made during a calendar year      or an academic year.       I would appreciate further information to see if the      problems I have found with these two Physicians are systemic      within the University System.                     INSTITUTIONAL AND NIH POLICIES       The Texas System requires that all compensation (income or      monetary value given in return for services) be reported. Its      policies consider compensation in the aggregate that meet or      exceeded $10,000 for the current calendar year, or are      expected to meet or exceed that amount in the next 12 months,      to be a significant financial interest.       Further, federal regulations place several requirements on      a university/hospital when its researchers apply for NIH      grants. These regulations are intended to ensure a level of      objectivity in publicly funded research, and state in      pertinent part that NIH investigators must disclose to      their institution any ``significant financial interest''      that may appear to affect the results of a study. NIH      interprets ``significant financial interest'' to mean at      least $10,000 in value or 5 percent ownership in a single      entity.       Based upon information available to me, it appears that      each of the Physicians identified above received NIH grants      to conduct studies. During the years 2003-2005, Dr. Rush      received an NIH grant to conduct a clinical intervention      training program that was to provide trainees with, among      other things, ``. . . knowledge and experience in the proper      conduct of clinical intervention research, ethics, human      subjects issues . . .'' However, my inquiry discovered that      Dr. Rush did not disclose all of the drug and device industry      payments to the University. For example, in 2001, Dr. Rush      disclosed $3,000 in outside income for his work as an      Advisory Board member for the Eli Lilly Company (Lilly). In      contrast, Lilly reported to me that it paid Dr. Rush $17,802      for advisory services that year.       For calendar years 2000 through 2008, Dr. Wagner led NIH-     funded studies on depression. These studies involved drugs      produced by Lilly (Prozac) and GlaxoSmithKline (GSK) (Paxil).      Lilly reported to me that it paid Dr. Wagner over $11,000 in      2002. However, and based upon the information in my      possession, Dr. Wagner did not disclose this payment to the      University in 2002 the first year that UTMB required      financial disclosures from its faculty.       It seems that Dr. Wagner also did not report payments she      received from GSK. GSK reported paying Dr. Wagner $53,220 in      2000--the first year of the NIH grant. Further, GSK reported      paying her $18,255 in 2001, and $34,961 in 2002 and $31,799      in 2003. Between the years of 2000 through 2005, GSK reported      paying Dr. Wagner $160,404. The only report Dr. Wagner made      of these payments was in 2005 when she reported $600 from      GSK.       In light of the information set forth above, I ask your      continued cooperation in examining conflicts of interest. In      my opinion, institutions across the United States must be      able to rely on the representations of its faculty to ensure      the integrity of medicine, academia, and the grant-making      process. At the same time, should the Physician Payments      Sunshine Act become law, institutions like yours will be able      to access a database that will set forth the payments made to      all doctors, including your faculty members.       Accordingly, I request that your respective institutions      respond to the following questions and requests for      information. For each response, please repeat the enumerated      request and follow with the appropriate answer.       (1) For each of the NIH grants received by the Physicians,      please confirm that the Physicians reported to the University      of Texas System's designated official ``the existence of [a]      conflicting interest.'' Please provide separate responses for      each grant received for the period from January 1, 2000 to      the present, and provide any supporting documentation for      each grant identified.       (2) For each grant identified above, please explain how the      University ensured ``that the interest has been managed,      reduced, or eliminated.'' Please provide an individual      response for each grant that each of the Physicians received      from January 2000 to the present, and provide any      documentation to support each claim.       (3) Please report on the status of the University's review      of the discrepancies in the financial disclosures made by      Drs. Rush and Wagner to the University, including what      action, if any, will be considered.       (4) For Drs. Rush and Wagner, please report whether a      determination can be made as to whether or not there is/was a      violation of the guidelines governing clinical trials and the      need to report conflicts of interest to an institutional      review board (IRB). Please respond by naming each clinical      trial for which the doctor was the principal investigator,      along with confirmation that conflicts of interest were      reported, if possible.       (5) Please provide a total dollar figure for all NIH monies      received annually by the Texas System. This request covers      the period of 2000 through 2007.       (6) Please provide a list of all NIH grants received by the      University of Texas System. This request covers the period of      2000 through 2007. For each grant please provide the      following:       a. Primary Investigator;       b. Grant Title;       c. Grant number;       d. Brief description; and       e. Amount of Award.       Thank you again for your continued cooperation and      assistance in this matter. As you know, in cooperating with      the Committee's review, no documents, records, data or      information related to these matters shall be destroyed,      modified, removed or otherwise made inaccessible to the      Committee.       I look forward to hearing from you by no later than      September 23, 2008. All documents responsive to this request      should be sent electronically in PDF format to      [emailÂ protected] If you have any      questions, please do not hesitate to contact Paul Thacker      (202) 224-4515.           Sincerely,                                              Charles E. Grassley,                                                   Ranking Member.       Attachment.    SELECTED DISCLOSURES BY DR. RUSH AND RELATED INFORMATION REPORTED BY PHARMACEUTICAL COMPANIES AND DEVICE                                                  MANUFACTURERS----------------------------------------------------------------------------------------------------------------                                                                 Disclosure filed with                 Year                          Company                institution        Amount company reported----------------------------------------------------------------------------------------------------------------2000.................................  Bristol-Myers Squibb...  $4,000.................                   $2,576                                       Eli Lilly..............  Not reported...........                    7,718                                       Merck..................  23,800.................                      n/a                                       Pfizer.................  No amount provided.....                    1,0002001.................................  Bristol-Myers Squibb...  Not reported...........                    2,921                                       Eli Lilly..............  3,000..................                   17,802                                       Merck \1\..............  30,000.................                      n/a                                       Merck \2\..............  30,600.................                      n/a2002.................................  Bristol-Myers Squibb...  No amount provided.....                    5,000                                       Eli Lilly..............  3,000..................                    4,500                                       Merck..................  70,000.................                      n/a                                       Pfizer.................  No amount provided.....                    7,5002003.................................  Bristol-Myers Squibb...  No amount provided.....                      250                                       Cyberonics.............  25,000.................                   75,000                                       Eli Lilly..............  3,000..................                        0                                       Merck..................  40,000.................                      n/a2004.................................  Bristol-Myers Squibb...  250....................                      750                                       Cyberonics.............  56,250.................                   75,000                                       Eli Lilly..............  2,000..................                    2,000                                       Forst Pharmaceuticals..  5,000..................                      n/a                                       Telesessions (Forest     18,000.................                      n/a                                        Labs).2005.................................  Cyberonics.............  \3\ 25,200.............               62,000 \5\                                       Eli Lilly..............  2,000..................                        0                                       Merck \4\..............  14,000.................                      n/a                                       Telesessions (Forest     \6\ 15,000.............                      n/a                                        Labs).2006.................................  Cyberonics.............  10,000.................              \5\ 100,000                                       Telesessions (Forest     \7\ 25,000.............                      n/a                                        Labs).2007.................................  Pfizer.................  2,000..................                    2,000----------------------------------------------------------------------------------------------------------------\1\ Dr. Rush reported on 7/11/01 statement of financial interests for serving as advisory board member.\2\ Dr. Rush reported in a request for prior approval of outside employment for services as consultant to U.S.  Strategic Advisory Board for Substance P Antagonists.\3\ Dr. Rush reported in a request for prior approval of outside employment for $600 per hour (October 1, 2005  to October 1, 2007) for a maximum of 42 hours each calendar quarter. Payment for services as Chair of  Depression Scientific Advisory Board and Consultant on issues related to clinical studies involving the use of  vagus nerve stimulation therapy.\4\ Dr. Rush reported in a request for prior approval of outside employment for $3,500 per day (January 1, 2005  to December 31, 2006) for 4 days per year plus teleconferences. Payment for services as Insomnia Advisory  Board Member.\5\ Payments reported by Cyberonics for consultation services performed during the year shown, although some of  the checks were issued in a different year.\6\ Dr. Rush reported in a request for prior approval of outside employment for $1,000 per call (15 hours per  year). Payment for services as faculty speaker on a series of conference calls as an educational service to  physicians.\7\ Dr. Rush reported in a request for prior approval of outside employment for $1,000 per call (25 calls about  50 minutes each). Payment for services as faculty speaker on a series of conference calls as an educational  service to physicians. Note 1: When a Physician named a company in a disclosure but did not provide an amount, the text reads ``no  amount reported.'' When a Physician did not list the company in the disclosure, the column reads ``not  reported.'' The Committee contacted several companies for payment information and the notation n/a (not  available) reflects that a company was not contacted.Note 2: The Committee estimated that the payments Dr. Rush disclosed totaled about $600,000 during the period  January 2000 through June 2007. Information reported by the pharmaceutical companies indicate that they made  additional payments that are not reflected in his disclosures.   SELECTED DISCLOSURES BY DR. WAGNER AND RELATED INFORMATION REPORTED BY PHARMACEUTICAL COMPANIES AND DEVICE                                                  MANUFACTURERS----------------------------------------------------------------------------------------------------------------                                                                 Disclosure filed with                 Year                          Company                institution        Amount company reported----------------------------------------------------------------------------------------------------------------2000 \1\.............................  GlaxoSmithKline........  Not reported...........              \2\ $53,220                                       Pfizer.................  Not reported...........                    5,0002001 \1\.............................  Bristol-Myers Squibb...  Not reported...........                    4,194                                       GlaxoSmithKline........  Not reported...........               \3\ 18,255                                       Pfizer.................  Not reported...........                    3,0002002.................................  Eli Lilly..............  Not reported...........                   11,000                                       GlaxoSmithKline........  Not reported...........                   34,961                                       Pfizer.................  Not reported...........                    2,5002003.................................  Eli Lilly..............  Not reported...........                    9,750                                       GlaxoSmithKline........  Not reported...........                   31,799                                       Pfizer.................  Not reported...........                    6,3502004.................................  AstraZeneca............  Not reported...........                    2,100                                       Eli Lilly..............  Not reported...........                    8,632                                       GlaxoSmithKline........  Not reported...........                   17,371                                       Pfizer.................  Not reported...........                    1,0002005.................................  AstraZeneca............  2,100..................                        0                                       Abbott Labs............  14,000.................                      n/a                                       Eli Lilly..............  Not reported...........                      300                                       Pfizer.................  3,500..................                    6,000                                       GlaxoSmithKline........  600....................                \4\ 4,7962006.................................  Abbott Labs............  10,000.................                      n/a                                       Bristol-Myers Squibb...  5,400..................                    7,204                                       Eli Lilly..............  4,531..................                    4,5312007.................................  Bristol-Myers Squibb...  1,500..................                    1,500                                       Eli Lilly..............  3,281..................                    3,281----------------------------------------------------------------------------------------------------------------\1\ ``The University of Texas Medical Branch at Galveston's conflict of interest policy did not provide for  annual disclosures until 2002.\2\ Payments for 19 talks on Paxil.\3\ Payments for 7 talks on Paxil.\4\ Honorarium and Expense. Paxil Psychiatry Advisory Board Member. Waldorf Astoria, 301 Park Ave., New York,  NY. February 17, 2005. Note 1: When a Physician named a company in a disclosure but did not provide an amount, the text reads ``no  amount reported.'' When a Physician did not list the company in the disclosure, the column reads ``not  reported.'' The Committee contacted several companies for payment information and the notation n/a (not  available) reflects that a company was not contacted.Note 2: The Committee estimated the payments Dr. Wagner disclosed totaled about $100,000 during the period  January 2000 through June 2007. Information reported by the pharmaceutical companies indicate that they made  additional payments that are not reflected in her disclosures.[GRAPHIC] [TIFF OMITTED] TS09SE08.001                          ____________________